The neuropsychiatric symptoms of Alzheimer disease (AD) are a major source of caregiver burden, patient distress, and decreased quality of life. Symptoms such as agitation and aggression attract more attention and more therapeutic intervention as potential threats to patient and caregiver safety. But quieter symptoms, such as apathy, are far more common, particularly in the earlier stages of illness, and have an insidious and highly negative impact on clinical course. They have also been understudied, both in terms of their neurobiological underpinnings and the search for effective treatments.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Fredericks C. Methylphenidate for Apathy in Alzheimer Disease—Why Should We Care? JAMA Neurol. Published online September 27, 2021. doi:10.1001/jamaneurol.2021.2942
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: